These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9008776)

  • 1. Piracetam in the treatment of myoclonus: an overview.
    Van Vleymen B; Van Zandijcke M
    Acta Neurol Belg; 1996 Dec; 96(4):270-80. PubMed ID: 9008776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group.
    Ikeda A; Shibasaki H; Tashiro K; Mizuno Y; Kimura J
    Mov Disord; 1996 Nov; 11(6):691-700. PubMed ID: 8914096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of piracetam on urea-induced myoclonus in rats].
    Nanri M; Yamamoto A; Matsuura N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2000 May; 20(2):45-50. PubMed ID: 11062861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piracetam in the treatment of cortical myoclonus.
    Genton P; Guerrini R; Remy C
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():49-53. PubMed ID: 10338109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myoclonic spasms: their clinical and neurophysiological characteristics, aetiology and treatment].
    Erro ME; Navarro MC
    Rev Neurol; 2009 Jan; 48 Suppl 1():S1-6. PubMed ID: 19222008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of piracetam in vertigo.
    Oosterveld WJ
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():54-60. PubMed ID: 10338110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A pharmacological profile of piracetam (Myocalm), a drug for myoclonus].
    Tajima K; Nanri M
    Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):209-14. PubMed ID: 11084917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus.
    Pranzatelli MR; Tate ED; Galvan I; Wheeler A
    Clin Neuropharmacol; 2001; 24(6):352-7. PubMed ID: 11801811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical challenge of posthypoxic myoclonus.
    Frucht SJ
    Adv Neurol; 2002; 89():85-8. PubMed ID: 11968475
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of myoclonus.
    Van Zandijcke M
    Acta Neurol Belg; 2003 Jun; 103(2):66-70. PubMed ID: 12891998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimyoclonic effect of levetiracetam in MERRF syndrome.
    Mancuso M; Galli R; Pizzanelli C; Filosto M; Siciliano G; Murri L
    J Neurol Sci; 2006 Apr; 243(1-2):97-9. PubMed ID: 16414077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and long-term follow-up of post-anoxic myoclonus].
    Janszky J; Holló A; Halász P
    Orv Hetil; 2001 Sep; 142(38):2091-3. PubMed ID: 11697066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients.
    Ince Gunal D; Agan K; Afsar N; Borucu D; Us O
    J Clin Pharm Ther; 2008 Apr; 33(2):175-8. PubMed ID: 18315783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of encephalopathy and myoclonus with levetiracetam in a case of subacute sclerosing panencephalitis.
    Becker D; Patel A; Abou-Khalil BW; Pina-Garza JE
    J Child Neurol; 2009 Jun; 24(6):763-7. PubMed ID: 19151368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piracetam in the treatment of different types of myoclonus.
    Obeso JA; Artieda J; Quinn N; Rothwell JC; Luquin MR; Vaamonde J; Marsden CD
    Clin Neuropharmacol; 1988 Dec; 11(6):529-36. PubMed ID: 3233590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic effect of levetiracetam on posthypoxic myoclonus: difficult weaning from mechanical ventilation.
    Muslu B; Kilci O; Horasanli E; Dikmen B
    Clin Neuropharmacol; 2009; 32(4):236. PubMed ID: 19644236
    [No Abstract]   [Full Text] [Related]  

  • 17. [Improvement of action myoclonus in a patient with dentatorubral-pallidoluysian atrophy by piracetam].
    Hirose M; Yokoyama H; Noguchi R; Haginoya K; Aoki M; Iinuma K
    No To Hattatsu; 2004 Jan; 36(1):75-9. PubMed ID: 14737869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of myoclonus in SCA2 by piracetam.
    De Rosa A; Striano P; Barbieri F; de Falco A; Rinaldi C; Tucci T; Striano S; Filla A; De Michele G
    Mov Disord; 2006 Jan; 21(1):116-8. PubMed ID: 16149096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective estimate of the nursing cost of autonomy impairment and cost benefit in clinical trials: feasibility and application of piracetam in demented elderly patients.
    Vlietinck R; Van Loon H; Van de Broele H; Tormans G
    Adv Ther; 1993; 10(5):226-44. PubMed ID: 10172000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.
    Magaudda A; Gelisse P; Genton P
    Epilepsia; 2004 Jun; 45(6):678-81. PubMed ID: 15144434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.